Polymer stealthing and mucin-1 retargeting for enhanced pharmacokinetics of an oncolytic vaccinia virus

Polymer stealthing and mucin-1 retargeting for enhanced pharmacokinetics of an oncolytic vaccinia virus

Vaccinia Virus (VV) is a powerful tool for cancer treatment with the potential for tumour tropism, efficient cell-to-cell spread, rapid replication in cancer cells and stimulation of anti-tumour immunity. It has a well-defined safety profile and is being assessed in late-stage clinical trials. Howev...

Bibliografske podrobnosti
Main Authors:	Hill, C, Grundy, M, Bau, L, Wallington, S, Balkaran, J, Ramos, V, Fisher, K, Seymour, L, Coussios, C, Carlisle, RC
Format:	Journal article
Jezik:	English
Izdano:	Cell Press 2021

Podobne knjige/članki

Polymer stealthing and mucin-1 retargeting for enhanced pharmacokinetics of an oncolytic vaccinia virus
od: Claudia Hill, et al.
Izdano: (2021-06-01)

Goldnanoparticles for the enhancement ofadenovirus stealthing
od: Mo, S, et al.
Izdano: (2013)

Polymeric cups for cavitation mediated delivery of oncolytic vaccinia virus
od: Myers, R, et al.
Izdano: (2016)

Retargeting of Viruses to Generate Oncolytic Agents
od: M. H. Verheije, et al.
Izdano: (2012-01-01)

HPMA copolymers for masking and retargeting of therapeutic viruses.
od: Fisher, K, et al.
Izdano: (2010)

Investigation of strategies to enhance the delivery of oncolytic vaccinia virus
od: Hill, C
Izdano: (2020)

Enhanced tumor uptake and penetration of virotherapy using polymer stealthing and focused ultrasound.
od: Carlisle, R, et al.
Izdano: (2013)

Cavitation-enhanced delivery of a self-amplifying oncolytic adenovirus for tumour-selective cancer therapy.
od: Carlisle, R, et al.
Izdano: (2012)

Tropism ablation and stealthing of oncolytic adenovirus enhances systemic delivery to tumors and improves virotherapy of cancer.
od: Green, N, et al.
Izdano: (2012)

Ultrasound-enhanced delivery of polymer-coated oncolytic adenovirus for tumour growth inhibition
od: Carlisle, R, et al.
Izdano: (2011)

Innovative retargeted oncolytic herpesvirus against nectin4-positive cancers
od: Andrea Vannini, et al.
Izdano: (2023-05-01)

Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies
od: Fisher, K, et al.
Izdano: (2001)

Oncolytic vaccinia virus and cancer immunotherapy
od: Lihua Xu, et al.
Izdano: (2024-01-01)

Theranostic Potential of Oncolytic Vaccinia Virus
od: Juan J Rojas, Steve H Thorne
Izdano: (2012-01-01)

Immunotherapeutic Potential of Oncolytic Vaccinia Virus
od: Stephen eThorne
Izdano: (2014-06-01)

Corrigendum: Innovative retargeted oncolytic herpesvirus against nectin4-positive cancers
od: Andrea Vannini, et al.
Izdano: (2024-06-01)

HSV as A Platform for the Generation of Retargeted, Armed, and Reporter-Expressing Oncolytic Viruses
od: Laura Menotti, et al.
Izdano: (2018-06-01)

Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy
od: Julia Niemann, et al.
Izdano: (2019-07-01)

Glycoviruses: chemical glycosylation retargets adenoviral gene transfer.
od: Pearce, O, et al.
Izdano: (2005)

Optimally stealthed Adenovirus serotype 5 shows enhanced activity and resistance to neutralisation
od: Thoma, C, et al.
Izdano: (2011)

Cavitation-enhanced delivery of a replicating oncolytic adenovirus to tumors using focused ultrasound.
od: Bazan-Peregrino, M, et al.
Izdano: (2013)

Specificity, Safety, Efficacy of EGFRvIII-Retargeted Oncolytic HSV for Xenotransplanted Human Glioblastoma
od: Irene Appolloni, et al.
Izdano: (2021-08-01)

Using Cystine Knot Proteins as a Novel Approach to Retarget Oncolytic Measles Virus
od: Sangeet Lal, et al.
Izdano: (2017-12-01)

Potent anti-tumor effects of receptor-retargeted syncytial oncolytic herpes simplex virus
od: Takuma Suzuki, et al.
Izdano: (2021-09-01)

Oncolytic Vaccinia Virus in Lung Cancer Vaccines
od: Cao-Sang Truong, et al.
Izdano: (2022-02-01)

Oncolytic vaccinia therapy of squamous cell carcinoma
od: Yu Yong A, et al.
Izdano: (2009-07-01)

Retargeting adenovirus gene therapy via the epidermal growth factor receptor
od: Morrison, J, et al.
Izdano: (2006)

Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor.
od: Morrison, J, et al.
Izdano: (2008)

Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia
od: Yi Wang, et al.
Izdano: (2021-09-01)

Achieving systemic delivery of oncolytic viruses
od: Hill, C, et al.
Izdano: (2019)

Recent progress in combination therapy of oncolytic vaccinia virus
od: Seyedeh Nasim Mirbahari, et al.
Izdano: (2024-03-01)

Coating of adeno-associated virus with reactive polymers can ablate virus tropism, enable retargeting and provide resistance to neutralising antisera.
od: Carlisle, R, et al.
Izdano: (2008)

Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics
od: Zong Sheng Guo, et al.
Izdano: (2019-01-01)

Expression of CCL19 from Oncolytic Vaccinia Enhances Immunotherapeutic Potential while Maintaining Oncolytic Activity
od: Jun Li, et al.
Izdano: (2012-12-01)

Cetuximab retargeting of adenovirus via the epidermal growth factor receptor for treatment of intraperitoneal ovarian cancer.
od: Morrison, J, et al.
Izdano: (2009)

Nanobody-based retargeting of an oncolytic herpesvirus for eliminating CXCR4+ GBM cells: A proof of principle
od: Judit Sanchez Gil, et al.
Izdano: (2022-09-01)

Oncolytic potency of HER-2 retargeted VSV-FH hybrid viruses: the role of receptor ligand affinity
od: Camilo Ayala Breton, et al.
Izdano: (2015-01-01)

HPB P26 Ex vivo normothermic perfusion of liver, kidney and spleen to predict human pharmacokinetics and assess drug delivery
od: Clark, T, et al.
Izdano: (2023)

Preclinical therapy of disseminated HER-2⁺ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus.
od: Patrizia Nanni, et al.
Izdano: (2013-01-01)

Ultrasound-induced cavitation enhances the delivery and therapeutic efficacy of an oncolytic virus in an in vitro model
od: Bazan-Peregrino, M, et al.
Izdano: (2012)